Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
NHS, Alzheimer's
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of
Alzheimer
's disease is too expensive for too little benefit to be used on the
NHS
in England, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year. But the National Institute ...
Alzheimer’s wonder drug blocked on NHS over cost
The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for the disease safe for use but the rationing body has immediately ruled that it is too expensive for NHS patients.
'It will be too late for him' - New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments.
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money - Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England
UK's NHS to block Eli Lilly's Alzheimer's drug on Wednesday, Telegraph reports
Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients, the Telegraph reported on Tuesday.
Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being
Pioneering Alzheimer's drug rejected for widespread use in NHS in England
A new pioneering Alzheimer's drug has been rejected for widespread use in the NHS in England. The announcement comes as the UK's medicines regulator said that donanemab could be licenced for use in the UK.
'Alzheimer's drugs will come too late for us'
A couple from Hull have called on the government to fund new Alzheimer's drugs, even though they say it will come "too late" to help them. Elaine Windass, whose husband, Brian, was diagnosed with Alzheimer's Disease in 2022,
Live news: Second Alzheimer’s drug deemed too expensive for UK’s NHS
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.
ITV
5h
Alzheimer’s drug rejected for NHS use: What is Donanemab?
A pioneering new drug, which has been shown to slow the advance of
Alzheimer
's, will not be available to patients on the
NHS
as Ian Woods reports. A new "effective"
Alzheimer
's drug has been ...
Outsourcing-pharma
9h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Manchester Evening News on MSN
13h
New Alzheimer’s drug donanemab rejected for widespread use in NHS
A new
Alzheimer
’s drug has been rejected by the health spending watchdog for general use within
NHS
England, with the ...
1d
on MSN
Why thousands of dementia sufferers are being denied the new miracle drug
In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback